CLINICAL CORE There is now abundant evidence that the pathology of Alzheimer's disease and related disorders (collectively referred to as AD) begins decades before the onset of clinical symptoms. This prodromal, preclinical period, while appearing cognitively and functionally silent is in fact associated with robust changes that may be detected by biomarkers and presents an ideal opportunity for early detection and intervention. To do this, we have taken the lead in developing and validating novel and innovative clinical-cognitive-behavioral measurements to identify individuals at-risk and combine these findings with state-of-art biomarker studies. The NYU ADC current research focus is on individuals with NIA-AA Stages 1 to 3 (particular focus on subjective memory complaints, CSF and imaging biomarkers, and physical functionality): preclinical disease, MCI, and mild AD compared with healthy aging (NIA-AA preclinical stage 0). The overall goal of the Clinical Core is to provide accurate research diagnoses for a cohort of longitudinally followed older adults to autopsy to provide appropriate subjects and subject-derived materials for research projects conducted by ADC investigators and collaborating scientists. This focus directly serves the primary research theme of the NYU ADC: the characterization of preclinical AD and its transition to MCI and early AD. We propose 8 Specific Aims: (1) Maintain and characterize an active UDS cohort of ~400 individuals (Clinical Dementia Rating [CDR] 0 50% of cohort), MCI (CDR 0.5 30% of cohort), or mild AD (CDR 0.5 or 1 20% of cohort); (2) Recruit, assess, and retain new participants (~45) from diverse backgrounds to replenish the cohort in proportion to attritional losses; (3) Provide culturally-sensitive recruitment strategies and longitudinal research assessments; (4) Collect, store, and distribute CSF, blood, and DNA biospecimens; (5) Obtain consent for brain donations; (6) Provide appropriate subjects, data, and biospecimens for research studies; (7) Integrate data collection and quality control procedures; and (8) provide infrastructure, resources, and coordinate contribution to NACC and other national and international collaborations. By providing a wealth of standardized longitudinal clinical, cognitive, biomarker, and neuroimaging data to investigators, the NYU ADC Clinical Core is poised to play a significant role in providing the infrastructure and resources necessary to advance our understanding of preclinical AD and its transition to the symptomatic stages of MCI and mild AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG008051-29
Application #
9514733
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
29
Fiscal Year
2018
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Kochunov, Peter; Dickie, Erin W; Viviano, Joseph D et al. (2018) Integration of routine QA data into mega-analysis may improve quality and sensitivity of multisite diffusion tensor imaging studies. Hum Brain Mapp 39:1015-1023
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:
Adhikari, Bhim M; Jahanshad, Neda; Shukla, Dinesh et al. (2018) Heritability estimates on resting state fMRI data using ENIGMA analysis pipeline. Pac Symp Biocomput 23:307-318
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Solesio, MarĂ­a E; Peixoto, Pablo M; Debure, Ludovic et al. (2018) Carbonic anhydrase inhibition selectively prevents amyloid ? neurovascular mitochondrial toxicity. Aging Cell :e12787
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211

Showing the most recent 10 out of 604 publications